Category: Disclosures

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary ALTEOGEN will list an additional 28,055 common shares on March 20, 2026, following the conversion of preferred shares into common shares. 📊 [Key Disclosure Details & Major Figures Summary] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verification of Total Outstanding Shares Update Following Additional Listing This…

Read More “[Disclosure] ALTEOGEN (196170) – Additional Listing (Conversion of Preferred Shares into Common Shares) / 2026-03-17” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion has signed a contract manufacturing agreement (CMO) worth KRW 294.9B (8.29% of recent annual revenue) with a global pharmaceutical company. 📊 [Key Disclosure Details & Financial Summary] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verification of Supply Commencement in Q1 2027 and Contract Execution Progress…

Read More “[Disclosure] Celltrion (068270) – Single Sales / Supply Contract / 2026-03-17” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary ALTEOGEN will hold its 18th Annual General Meeting of Shareholders on March 31, 2026, at the Daejeon Convention Center. Agenda items include approval of financial statements (KRW 371 dividend per share), amendments to Articles of Incorporation, appointments of directors and Audit Committee members, and reduction of…

Read More “[Disclosure] ALTEOGEN (196170) – Resolution on Convocation of General Meeting of Shareholders / 2026-03-16” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion has received an ‘Unqualified’ audit opinion from Samil PwC for both consolidated and separate financial statements, reporting FY2025 consolidated revenue of KRW 4.16T and operating profit of KRW 1.17T. 📊 [Key Disclosure Details & Financial Summary] [Consolidated Financial & Earnings Summary] [Separate Financial & Earnings…

Read More “[Disclosure] Celltrion (068270) – Submission of Audit Report / 2026-03-16” »